|
|
Volumn 31, Issue 6, 2016, Pages 1245-1246
|
|
HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
BEVACIZUMAB;
CETUXIMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
PANITUMUMAB;
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR;
HRAS PROTEIN, HUMAN;
PROTEIN P21;
ADULT;
ALLERGIC REACTION;
BONE METASTASIS;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RESISTANCE;
CANCER SURGERY;
CASE REPORT;
COLON CANCER;
COLON RESECTION;
DRUG RESPONSE;
DRUG WITHDRAWAL;
FOLLOW UP;
HUMAN;
LETTER;
LIVER METASTASIS;
LUNG BIOPSY;
LUNG METASTASIS;
MALE;
MEDICAL HISTORY;
MIDDLE AGED;
MULTIPLE CYCLE TREATMENT;
NEXT GENERATION SEQUENCING;
ONCOGENE H RAS;
ONCOGENE K RAS;
ONCOGENE N RAS;
PHARMACOGENETICS;
PRIORITY JOURNAL;
RECURRENT DISEASE;
SHOCK;
SOMATIC MUTATION;
ANTAGONISTS AND INHIBITORS;
COLORECTAL NEOPLASMS;
DRUG RESISTANCE;
GENETICS;
METABOLISM;
MUTATION;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
MALE;
MIDDLE AGED;
MUTATION;
PROTO-ONCOGENE PROTEINS P21(RAS);
RECEPTOR, EPIDERMAL GROWTH FACTOR;
|
|
EID: 84946762385
PISSN: 01791958
EISSN: 14321262
Source Type: Journal
DOI: 10.1007/s00384-015-2448-7 Document Type: Letter |
|
Times cited : (6)
|
|
References (0)
|
